IXICO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.125 GBX | 0.00% |
|
-5.80% | -35.00% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
Calendar
21/05/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.00% | 4.93M | |
| +22.66% | 47.9B | |
| +46.56% | 41.42B | |
| -1.96% | 40.7B | |
| -6.20% | 28.92B | |
| +11.37% | 25.55B | |
| -21.38% | 19.27B | |
| -1.04% | 12.15B | |
| +30.44% | 12.14B | |
| -0.83% | 11.99B |
- Stock Market
- Equities
- IXI Stock
- News IXICO plc
- Ixico : Expands Rare Disease Franchise With $5 Million Contract Win
